drugset / Trial / NCT00969046

Dose-Escalation Study in Advanced Colon Cancer Patients

NCT00969046

Phase 1 Completed 60 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is exploring different administration schedules (short versus prolonged infusion) to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with pretreated advanced colon cancer.

Timeline

Start
2003-11
Primary completion
2006-11
Completion
2006-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Patupilone Small molecule Other

Indications